Jia Luo, MD
@jia-luo.bsky.social
Thoracic medical oncologist and cancer researcher at Dana-Farber/ Harvard Cancer Center
// Prev MSKCC Fellow, OHSU IM & Chief Res, Stanford Med, and UW-Madison
https://t.co/Y9HwVQ1jyq
// Prev MSKCC Fellow, OHSU IM & Chief Res, Stanford Med, and UW-Madison
https://t.co/Y9HwVQ1jyq
Congratulations, Juan!!
August 15, 2025 at 6:21 PM
Congratulations, Juan!!
End/ Thank you to 💫 first author @justinjkim.bsky.social, Prof French, co-author experts and collaborators, our patients, and funding sources, including NIH NCI
Accompanying article: www.dana-farber.org/newsroom/new... @danafarber.bsky.social @danafarbernews.bsky.social @harvardmed.bsky.social
Accompanying article: www.dana-farber.org/newsroom/new... @danafarber.bsky.social @danafarbernews.bsky.social @harvardmed.bsky.social
July 28, 2025 at 11:22 AM
End/ Thank you to 💫 first author @justinjkim.bsky.social, Prof French, co-author experts and collaborators, our patients, and funding sources, including NIH NCI
Accompanying article: www.dana-farber.org/newsroom/new... @danafarber.bsky.social @danafarbernews.bsky.social @harvardmed.bsky.social
Accompanying article: www.dana-farber.org/newsroom/new... @danafarber.bsky.social @danafarbernews.bsky.social @harvardmed.bsky.social
4/ In summary, if NUT carcinoma is suspected clinically – eg in a poorly differentiated aggressive cancer of lung, head or neck origin - clinicians should discuss with pathology colleagues whether a gold standard test for NUT carcinoma should be ordered
Our paper also includes co-mutations, fusions
Our paper also includes co-mutations, fusions
July 28, 2025 at 11:22 AM
4/ In summary, if NUT carcinoma is suspected clinically – eg in a poorly differentiated aggressive cancer of lung, head or neck origin - clinicians should discuss with pathology colleagues whether a gold standard test for NUT carcinoma should be ordered
Our paper also includes co-mutations, fusions
Our paper also includes co-mutations, fusions
3/ Using our international registry (nc-registry.org), we found that while more DNA NGS panels are including NUT carcinoma defining fusion genes, this did not improve detection
Of note, NUT IHC (turnaround time ~7 days) is 100% specific in these cases
NUT IHC/FISH and RNA fusion are gold standards
Of note, NUT IHC (turnaround time ~7 days) is 100% specific in these cases
NUT IHC/FISH and RNA fusion are gold standards
July 28, 2025 at 11:22 AM
3/ Using our international registry (nc-registry.org), we found that while more DNA NGS panels are including NUT carcinoma defining fusion genes, this did not improve detection
Of note, NUT IHC (turnaround time ~7 days) is 100% specific in these cases
NUT IHC/FISH and RNA fusion are gold standards
Of note, NUT IHC (turnaround time ~7 days) is 100% specific in these cases
NUT IHC/FISH and RNA fusion are gold standards
2/ WHY does it matter?
🧬 NUT carcinoma is fusion oncogene driven and aggressive, with no FDA approved treatments
Non-metastatic diagnosis needs multi-D evaluation to give patients the best chance
Clinical trials should be considered for a metastatic diagnosis
Ref: www.jto.org/article/S155...
🧬 NUT carcinoma is fusion oncogene driven and aggressive, with no FDA approved treatments
Non-metastatic diagnosis needs multi-D evaluation to give patients the best chance
Clinical trials should be considered for a metastatic diagnosis
Ref: www.jto.org/article/S155...
Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma
NUT carcinoma (NC) is an underdiagnosed and aggressive poorly differentiated or squamous
cell cancer. A subset of NC is sensitive to chemotherapy, but the optimal regimen
is unknown. Experts have reco...
www.jto.org
July 28, 2025 at 11:22 AM
2/ WHY does it matter?
🧬 NUT carcinoma is fusion oncogene driven and aggressive, with no FDA approved treatments
Non-metastatic diagnosis needs multi-D evaluation to give patients the best chance
Clinical trials should be considered for a metastatic diagnosis
Ref: www.jto.org/article/S155...
🧬 NUT carcinoma is fusion oncogene driven and aggressive, with no FDA approved treatments
Non-metastatic diagnosis needs multi-D evaluation to give patients the best chance
Clinical trials should be considered for a metastatic diagnosis
Ref: www.jto.org/article/S155...